亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

In vivo screening of anticancer drugs against multiple cell lines in a single live host

總結: 70% of the nearly $1 billion spent on bringing each new small-molecule anticancer drug to market is spent on clinical trials. A significant part of this cost is attributed to the failure of many drugs early on in trials due to lack of efficacy. While animal models can help predict clinical efficacy in humans, these models typically only allow the testing of a drug candidate against a single cancer cell type at a time, which substantially slows the discovery process. This technology is an implantable microfluidic device that can hold dozens of live tumor spheroids generated from different cell lines, allowing simultaneous evaluation of a drug against multiple cancers in a single animal.

技術優勢: High-throughput—allows multiple cell lines to be tested simultaneouslyReduces the number of animals needed for pre-clinical studiesPotentially reduces the cost and amount of time required for pre-clinical in vivo drug screeningPatent Information:Patent Pending (US 20160324991)Tech Ventures Reference: IR CU12067

技術應用: Pre-clinical in vivo screening of anticancer drugsResearch tool for determining the mechanism of action of anti-cancer dugsResearch tool for identifying causes of cancer drug resistanceTesting host response to different biomaterials

*Inquiry: Beth KaudererColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

欲了解更多信息，請點擊這裡